2026-08-29T14:04:46Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/68892025-04-29T10:29:48Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Scorzoni, Liliana author de Lucas, Maria Pilar author Mesa-Arango, Ana Cecilia author Fusco-Almeida, Ana Marisa author Lozano, Encarnacion author Cuenca-Estrella, Manuel author Mendes-Giannini, Maria José Soares author Zaragoza, Oscar author 2013-03-28 The incidence of opportunistic fungal infections has increased in recent decades due to the growing proportion of immunocompromised patients in our society. Candida krusei has been described as a causative agent of disseminated fungal infections in susceptible patients. Although its prevalence remains low among yeast infections (2-5%), its intrinsic resistance to fluconazole makes this yeast important from epidemiologic aspects. Non mammalian organisms are feasible models to study fungal virulence and drug efficacy. In this work we have used the lepidopteran Galleria mellonella and the nematode Caenorhabditis elegans as models to assess antifungal efficacy during infection by C. krusei. This yeast killed G. mellonella at 25, 30 and 37°C and reduced haemocytic density. Infected larvae melanized in a dose-dependent manner. Fluconazole did not protect against C. krusei infection, in contrast to amphotericin B, voriconazole or caspofungin. However, the doses of these antifungals required to obtain larvae protection were always higher during C. krusei infection than during C. albicans infection. Similar results were found in the model host C. elegans. Our work demonstrates that non mammalian models are useful tools to investigate in vivo antifungal efficacy and virulence of C. krusei. PLoS One. 2013;8(3):e60047 10.1371/journal.pone.0060047 1932-6203 1932-6203 PloS one 23555877 http://hdl.handle.net/20.500.12105/6889 Antifungal efficacy during Candida krusei infection in non-conventional models correlates with the yeast in vitro susceptibility profile